Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center
- PMID: 38992933
- PMCID: PMC11302479
- DOI: 10.12659/MSM.943529
Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center
Abstract
BACKGROUND Heart failure and end-stage renal disease often coexist, and management of heart failure can be challenging in patients during hemodialysis. Sacubitril-valsartan (SV) is the first drug to receive regulatory approval for use in patients with chronic heart failure with reduced ejection fraction (HFrEF) and New York Heart Association (NYHA) classification II, III, or IV. This study aimed to evaluate the efficacy and safety of SV for use in chronic heart failure patients on maintenance hemodialysis (MHD). MATERIAL AND METHODS From September 2021 to October 2022, 28 patients on MHD with chronic heart failure at the hemodialysis center of Shaanxi Second Provincial People's Hospital were regularly followed. During the 12-week follow-up period, all patients were administered SV at doses of 100-400 mg per day. Biochemical indicators, echocardiographic parameters, life quality scores, and adverse events were evaluated. RESULTS We enrolled 28 patients. Compared with the baseline levels, NYHA class III in these patients treated with SV was significantly decreased from 60.71% to 32.14% (P<0.05), left ventricular ejection fraction (LVEF) was significantly improved from 44.29±8.92% to 53.32±7.88% (P<0.001), the Physical Component Summary (PCS) score was significantly improved from 40.0±6.41 to 56.20±9.86 (P<0.001), and the Mental Component Summary (MCS) score was significantly improved from 39.99±6.14 to 52.59±11.0 (P<0.001). CONCLUSIONS We demonstrated that SV improved NYHA classification and LVEF values of patients on MHD with chronic heart failure and also improved their quality of life.
Conflict of interest statement
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11302479/bin/medscimonit-30-e943529-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11302479/bin/medscimonit-30-e943529-g002.gif)
Similar articles
-
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.JAMA. 2021 Nov 16;326(19):1919-1929. doi: 10.1001/jama.2021.18463. JAMA. 2021. PMID: 34783839 Free PMC article. Clinical Trial.
-
Effect of Sacubitril/Valsartan on Patients Having Heart Failure With Preserved Left Ventricular Ejection Fraction Undergoing Hemodialysis: A Long-term Observational Study.In Vivo. 2024 May-Jun;38(3):1266-1270. doi: 10.21873/invivo.13564. In Vivo. 2024. PMID: 38688596 Free PMC article.
-
Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease.Cardiovasc Drugs Ther. 2024 Jun;38(3):505-515. doi: 10.1007/s10557-022-07421-0. Epub 2023 Jan 7. Cardiovasc Drugs Ther. 2024. PMID: 36609948 Free PMC article.
-
The safety of sacubitril-valsartan for the treatment of chronic heart failure.Expert Opin Drug Saf. 2017 Feb;16(2):257-263. doi: 10.1080/14740338.2017.1279144. Expert Opin Drug Saf. 2017. PMID: 28060547 Review.
-
Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.Am J Cardiovasc Drugs. 2019 Feb;19(1):1-10. doi: 10.1007/s40256-018-0306-z. Am J Cardiovasc Drugs. 2019. PMID: 30345485 Review.
References
-
- Khan MS, Ahmed A, Greene SJ, et al. Managing heart failure in patients on dialysis: state-of-the-art review. J Card Fail. 2023;29(1):87–107. - PubMed
-
- Jhund PS, Petrie MC, Robertson M, et al. Heart failure hospitalization in adults receiving hemodialysis and the effect of intravenous iron therapy. JACC Heart Fail. 2021;9:518–27. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical